(Q34750172)

4 August 2017

1 reference

title

NF-kappaB as a therapeutic target in cancer (English)

1 reference

4 August 2017

0 references

1

Robert Z Orlowski

1 reference

4 August 2017

Albert S Baldwin

2

1 reference

4 August 2017

publication date

1 August 2002

1 reference

Trends in Molecular Medicine

4 August 2017

published in

1 reference

4 August 2017

volume

8

1 reference

4 August 2017

issue

8

1 reference

4 August 2017

page(s)

385-389

1 reference

The NF-kappa B and I kappa B proteins: new discoveries and insights

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Aberrant rel/nfkb genes and activity in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

The role of Rel/NF-kappa B proteins in viral oncogenesis and the regulation of viral transcription

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Transcriptional cross talk between NF-kappaB and p53.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Role of NF-κB in p53-mediated programmed cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

The role of the ubiquitin-proteasome pathway in apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

History of the development of arsenic derivatives in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

NF-kappa B as a therapeutic target in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2802%2902375-4

7 January 2021

10.1016/S1471-4914(02)02375-4

Identifiers

DOI

1 reference

4 August 2017

1 reference